Pharmacy benefit manager ("PBM") Express Scripts will list Viatris' (VTRS+2.9%) insulin biosimilar Semglee (insulin glargine-yfgn) on its national preferred formulary.
The coverage begins on Jan. 1, 2022.
Express Scripts said the move will lead to $20M in cost savings in 2022.